Accès ouvert

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Article scientifique 2019 Anglais

Résumé

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

Citer ce document

Mohammed, A., Rashied, H., Elsayed, F. (2019). CDK4/6 inhibitors in advanced breast cancer, what is beyond?. https://doi.org/10.4081/oncol.2019.416

Accès au document

Ce lien n'est plus accessible actuellement. Contactez l'institution d'origine.

Auteur(s)

Amrallah A. Mohammed Hanaa Rashied Fifi Mostafa Elsayed

Statistiques

Consultations : 1

Téléchargements : 0